VANCOUVER, British Columbia & DALLAS - Alpha Cognition Inc. (NASDAQ:ACOG) announced today that Robert Wills has been elected Chairman of the Board of Directors, replacing Len Mertz, who retired after serving as chairman since 2021.
Wills has served on Alpha Cognition’s Board of Directors since 2025 and currently chairs the Governance and Nominating Committee and serves on the Audit Committee, according to a press release statement. The biopharmaceutical company develops therapies for neurodegenerative disorders.
Wills currently serves as Chairman of the Board at Milestone Pharmaceuticals Inc. (NASDAQ:MIST) and as a board member at Parion Sciences Inc. He previously served as Chairman of CymaBay Therapeutics (NASDAQ:CBAY) before its acquisition by Gilead Sciences Inc. in March 2024, and as a board member at Oncternal Therapeutics (NASDAQ:ONCT) from 2019 to 2025. He also served as Executive Chairman of GTx Inc. from 2015 to 2019.
Wills spent more than 25 years at Johnson & Johnson, where his positions included Vice President of Alliance Management at Janssen Pharmaceutical Companies and Senior Vice President of Global Development. He holds a B.S. in Biochemistry and an M.S. in Pharmaceutics from the University of Wisconsin and a Ph.D. in Pharmaceutics from the University of Texas.
"I am honored to serve as Chairman of the Board at this important stage in Alpha Cognition’s evolution," Wills said in the statement.
Chief Executive Officer Michael McFadden said Wills "brings a wealth of experience, strategic insight, and a deep understanding of our business." The company maintains a solid balance sheet with more cash than debt and boasts an impressive 87.5% gross profit margin on its ZUNVEYL product.
Alpha Cognition is a commercial stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases. The company’s product ZUNVEYL is an acetylcholinesterase inhibitor approved for treating mild-to-moderate Alzheimer’s disease in adults.
In other recent news, Alpha Cognition Inc. reported a significant increase in revenue for the first quarter of 2026, attributed to the commercialization of its Alzheimer’s treatment, ZUNVEYL. Despite this robust revenue growth, the company faced a larger net loss due to increased operating expenses. In addition, Alpha Cognition announced the enrollment of the first patient in RESOLVE, a Phase 4 post-marketing clinical study. This study is designed to evaluate the tolerability of ZUNVEYL in patients with Alzheimer’s disease. The RESOLVE study will gather safety and tolerability data while examining changes in Alzheimer’s disease-related neuropsychiatric symptoms. These developments mark important steps in Alpha Cognition’s ongoing efforts to enhance its treatment offerings and gather critical data on ZUNVEYL’s performance in real-world settings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy. Get the bottom line for ACOG plus thousands of other stocks and find your next hidden gem with massive upside.